Shanghai Bao said China’s National Medical Products Administration approved clinical trials of KJ101 for dissolving and removing gastric mucus during gastroscopy. The company said KJ101 previously received an NMPA IND approval for wound-healing indications in February 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260312-12049100), on March 12, 2026, and is solely responsible for the information contained therein.
Comments